Novartis AG
Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders

Abstract:

The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): ##STR00001## or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R.sub.1, R.sub.1, R.sub.1, R.sub.1, R.sub.1, R.sub.1, R.sub.1, R.sub.1, R.sub.1, X.sub.1, X.sub.2, and X.sub.3 are described herein.